Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Diabetic neuropathies: a statement by the American Diabetes Association.
Not all patients with peripheral nerve dysfunction have a neuropathy caused by diabetes, and effective symptomatic treatments are available for the manifestations of DPN and autonomic neuropathy. Expand
A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy
- E. Feldman, M. Stevens, P. K. Thomas, M. Brown, N. Canal, D. Greene
- Diabetes Care
- 1 November 1994
The results indicate that the MNSI is a good screening tool for diabetic neuropathy and that the MDNS coupled with nerve conductions provides a simple means to confirm this diagnosis. Expand
Diabetic Neuropathy: A Position Statement by the American Diabetes Association
Although screening for rarer atypical forms of diabetic neuropathy may be warranted, DSPN and autonomic neuropathy are the most common forms encountered in practice and the strongest available evidence regarding treatment pertains to these forms. Expand
Diabetic neuropathy: clinical manifestations and current treatments
- B. Callaghan, Hsinlin T Cheng, C. Stables, Andrea L. Smith, E. Feldman
- The Lancet Neurology
- 1 June 2012
Growing evidence supports an association between components of the metabolic syndrome, including prediabetes, and neuropathy, and studies are needed to further explore this association, which has implications for the development of new treatments for this common disorder. Expand
The insulin-like growth factor system and its pleiotropic functions in brain.
In vitro studies have demonstrated that the IGF system promotes differentiation and proliferation and sustains survival, preventing apoptosis of neuronal and brain derived cells and studies of transgenic mice overexpressing components of the IGFsystem or mice with disruptions of the same genes have clearly shown thatThe IGF system plays a key role in vivo. Expand
Diabetic neuropathy: mechanisms to management.
- J. L. Edwards, A. Vincent, Hsinlin T Cheng, E. Feldman
- Pharmacology & therapeutics
- 1 October 2008
This review covers the pathology, epidemiology, biochemical pathways, and prevention of diabetic neuropathy, as well as discusses current symptomatic and causal therapies and novel approaches to identify therapeutic targets. Expand
Oxidative stress in the pathogenesis of diabetic neuropathy.
Evidence is presented to support the idea that both chronic and acute hyperglycemia cause oxidative stress in the peripheral nervous system that can promote the development of diabetic neuropathy, and it is concluded that striving for superior antioxidative therapies remains essential for the prevention of neuropathy in diabetic patients. Expand
Loss of Myotubularin Function Results in T-Tubule Disorganization in Zebrafish and Human Myotubular Myopathy
It is demonstrated for the first time that myotubularin functions to regulate PI3P levels in a vertebrate in vivo, and that homologous myotubbularin-related proteins can functionally compensate for the loss of myotUBularin. Expand
Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren's syndrome
The possibility of Sjögren's syndrome should be considered in patients, especially women, who develop acute, subacute, or chronic sensory and autonomic neuropathies, with ataxia and kinesthetic loss. Expand
Loss of Miro1-directed mitochondrial movement results in a novel murine model for neuron disease
- Tammy T. Nguyen, S. Oh, +13 authors J. Shaw
- Biology, Medicine
- Proceedings of the National Academy of Sciences
- 18 August 2014
It is demonstrated that Miro1 is essential for development of cranial motor nuclei required for respiratory control and maintenance of upper motor neurons required for ambulation and that defects in mitochondrial motility and distribution are sufficient to cause neurological disease. Expand